Received: 26 June 2022
Accepted: 5 August 2022
First Online: 16 August 2022
: This study was approved by the University of Chicago Institutional Review Board (Approval No. 10-178B and 14-0482).
: Not applicable.
: C.H. and W.Z. were shareholders of Epican Technology, Ltd, which held a license of the 5hmC-Seal technique from the University of Chicago for clinical applications. C.H. is the founder of Accent Therapeutics, Inc. and a member of its scientific advisory board. The remaining authors declare no conflict of interests.